title: Genotype 3 Infection: The Last Stand of Hepatitis C Virus.
abstract: Hepatitis C virus (HCV) represents a significant global disease burden, with an estimated 130-150 million people worldwide living with chronic HCV infection. Within the six major clinical HCV genotypes, genotype 3 represents 22-30% of all infection and is described as a unique entity with higher rates of steatosis, faster progression to cirrhosis, and higher rates of hepatocellular carcinoma. Hepatic steatosis in the setting of hepatitis C genotype 3 (HCV-3) is driven by viral influence on three major pathways: microsomal triglyceride transfer protein, sterol regulatory element-binding protein-1c, and peroxisome proliferator-associated receptor-α. Historically with direct-acting antivirals, the rates of cure for HCV-3 therapies lagged behind the other genotypes. As current therapies for HCV-3 continue to close this gap, it is important to be cognizant of common drug interactions such as acid-suppressing medication and amiodarone. In this review, we discuss the rates of steatosis in HCV-3, the mechanisms behind HCV-3-specific steatosis, and current and future therapies.
authors.affiliation: Division of Infectious Diseases, Department of Medicine, Duke University School of Medicine, Durham, NC, USA.|Infectious Diseases Research, Duke Clinical Research Institute, Durham, NC, USA.
authors.forename: Austin
authors.initials: A
authors.lastname: Chan
authors.affiliation: Toronto Center for Liver Disease, University of Toronto, Toronto, ON, Canada.
authors.forename: Keyur
authors.initials: K
authors.lastname: Patel
authors.affiliation: Division of Infectious Diseases, Department of Medicine, Duke University School of Medicine, Durham, NC, USA. susanna.naggie@dm.duke.edu.|Infectious Diseases Research, Duke Clinical Research Institute, Durham, NC, USA. susanna.naggie@dm.duke.edu.
authors.forename: Susanna
authors.initials: S
authors.lastname: Naggie
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D005234:Fatty Liver / Q000209:etiology / Q000821:virology; D005838:Genotype; D016174:Hepacivirus / Q000145:classification / Q000187:drug effects / Q000235:genetics* / Q000472:pathogenicity*; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000821:virology*; D006801:Humans
chemical_list: D000998:Antiviral Agents